Literature DB >> 19919989

Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading.

Vijay Divakaran1, Julia Adrogue, Masakuni Ishiyama, Mark L Entman, Sandra Haudek, Natarajan Sivasubramanian, Douglas L Mann.   

Abstract

BACKGROUND: Previous studies suggest that transforming growth factor-beta provokes cardiac hypertrophy and myocardial fibrosis; however, it is unclear whether the deleterious effects of transforming growth factor-beta signaling are conveyed through SMAD-dependent or SMAD-independent signaling pathways. METHODS AND
RESULTS: To determine the contribution of SMAD-dependent signaling to cardiac remodeling, we performed transaortic constriction in SMAD3 null (SMAD3(-/-)) and littermate control mice (age, 10 to 12 weeks). Cumulative survival 20 days after transaortic constriction was significantly less in the SMAD3(-/-) mice when compared with littermate controls (43.6% versus 90.9%, P<0.01). Transaortic constriction resulted in a significant increase in cardiac hypertrophy in the SMAD3(-/-) mice, denoted by an increase in the heart weight to tibial length ratio and increased myocyte cross-sectional area. Loss of SMAD3 signaling also resulted in a significant 60% decrease in myocardial fibrosis (P<0.05). A microRNA microarray showed that 55 microRNAs were differentially expressed in littermate and SMAD3(-/-) mice and that 10 of these microRNAs were predicted to bind to genes that regulate the extracellular matrix. Of these 10 candidate microRNAs, both miR-25 and miR-29a were sufficient to decrease collagen gene expression when transfected into isolated cardiac fibroblasts in vitro.
CONCLUSIONS: The results suggest that SMAD3 signaling plays dual roles in the heart: one beneficial role by delimiting hypertrophic growth and the other deleterious by modulating myocardial fibrosis, possibly through a pathway that entails accumulation of microRNAs that decrease collagen gene expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19919989      PMCID: PMC3064555          DOI: 10.1161/CIRCHEARTFAILURE.108.823070

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  39 in total

Review 1.  Transcriptional control by the TGF-beta/Smad signaling system.

Authors:  J Massagué; D Wotton
Journal:  EMBO J       Date:  2000-04-17       Impact factor: 11.598

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 3.  Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.

Authors:  Y Y Li; C F McTiernan; A M Feldman
Journal:  Cardiovasc Res       Date:  2000-05       Impact factor: 10.787

4.  TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice.

Authors:  D Zhang; V Gaussin; G E Taffet; N S Belaguli; M Yamada; R J Schwartz; L H Michael; P A Overbeek; M D Schneider
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

5.  Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.

Authors:  N Sivasubramanian; M L Coker; K M Kurrelmeyer; W R MacLellan; F J DeMayo; F G Spinale; D L Mann
Journal:  Circulation       Date:  2001-08-14       Impact factor: 29.690

6.  Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3.

Authors:  W Yuan; J Varga
Journal:  J Biol Chem       Date:  2001-08-13       Impact factor: 5.157

7.  Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart.

Authors:  H Nakajima; H O Nakajima; O Salcher; A S Dittiè; K Dembowsky; S Jing; L J Field
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

8.  Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation.

Authors:  Kathleen C Flanders; Catherine D Sullivan; Makiko Fujii; Anastasia Sowers; Mario A Anzano; Alidad Arabshahi; Christopher Major; Chuxia Deng; Angelo Russo; James B Mitchell; Anita B Roberts
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

9.  Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice.

Authors:  Jingsong Zhao; Wei Shi; Yan-Ling Wang; Hui Chen; Pablo Bringas; Michael B Datto; Joshua P Frederick; Xiao-Fan Wang; David Warburton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-03       Impact factor: 5.464

Review 10.  The emerging role of microRNAs in cardiac remodeling and heart failure.

Authors:  Vijay Divakaran; Douglas L Mann
Journal:  Circ Res       Date:  2008-11-07       Impact factor: 17.367

View more
  42 in total

1.  Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3β and TGF-β1-Smad signalling.

Authors:  Ling Yan; Xiang Wei; Qi-Zhu Tang; Jinghua Feng; Yan Zhang; Chen Liu; Zhou-Yan Bian; Lian-Feng Zhang; Manyin Chen; Xue Bai; Ai-Bing Wang; John Fassett; Yingjie Chen; You-Wen He; Qinglin Yang; Peter P Liu; Hongliang Li
Journal:  Cardiovasc Res       Date:  2011-06-01       Impact factor: 10.787

Review 2.  Transforming growth factor beta signaling in adult cardiovascular diseases and repair.

Authors:  Thomas Doetschman; Joey V Barnett; Raymond B Runyan; Todd D Camenisch; Ronald L Heimark; Henk L Granzier; Simon J Conway; Mohamad Azhar
Journal:  Cell Tissue Res       Date:  2011-09-28       Impact factor: 5.249

Review 3.  Smad-mediated regulation of microRNA biosynthesis.

Authors:  Matthew T Blahna; Akiko Hata
Journal:  FEBS Lett       Date:  2012-01-28       Impact factor: 4.124

4.  Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and angiotensin II-transforming growth factor β (TGF-β1) signaling axis.

Authors:  Eduardo Mascareno; Josephine Galatioto; Inna Rozenberg; Louis Salciccioli; Haroon Kamran; Jason M Lazar; Fang Liu; Thierry Pedrazzini; M A Q Siddiqui
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

5.  Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure.

Authors:  Navin K Kapur; Szuhuei Wilson; Adil A Yunis; Xiaoying Qiao; Emily Mackey; Vikram Paruchuri; Corey Baker; Mark J Aronovitz; S Ananth Karumanchi; Michelle Letarte; David A Kass; Michael E Mendelsohn; Richard H Karas
Journal:  Circulation       Date:  2012-05-16       Impact factor: 29.690

Review 6.  Bone marrow mesenchymal stem cells for post-myocardial infarction cardiac repair: microRNAs as novel regulators.

Authors:  Zhuzhi Wen; Shaoxin Zheng; Changqing Zhou; Woliang Yuan; Jingfeng Wang; Tong Wang
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

7.  Angiotensin receptor type 1 single nucleotide polymorphism 1166A/C is associated with malignant arrhythmias and altered circulating miR-155 levels in patients with chronic heart failure.

Authors:  Raul R Blanco; Harland Austin; Richard N Vest; Ravinder Valadri; Wei Li; Bernard Lassegue; Qing Song; Barry London; Samuel C Dudley; Heather L Bloom; Charles D Searles; A Maziar Zafari
Journal:  J Card Fail       Date:  2012-08-09       Impact factor: 5.712

8.  Genetic deficiency of Smad3 protects the kidneys from atrophy and interstitial fibrosis in 2K1C hypertension.

Authors:  Gina M Warner; Jingfei Cheng; Bruce E Knudsen; Catherine E Gray; Ansgar Deibel; Justin E Juskewitch; Lilach O Lerman; Stephen C Textor; Karl A Nath; Joseph P Grande
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-29

9.  Cardiac epithelial-mesenchymal transition is blocked by monomethylarsonous acid (III).

Authors:  Tianfang Huang; Joey V Barnett; Todd D Camenisch
Journal:  Toxicol Sci       Date:  2014-08-21       Impact factor: 4.849

Review 10.  Role of the microRNA-29 family in myocardial fibrosis.

Authors:  Changyan Li; Nan Wang; Peng Rao; Limeiting Wang; Di Lu; Lin Sun
Journal:  J Physiol Biochem       Date:  2021-05-28       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.